The role of PET in Hodgkin's lymphoma and its impact on radiation oncology. - Wikidata - awgldk - TriplyDB

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

http://www.wikidata.org/entity/Q37788240

about

Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma Positron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patients

P2860

Q24186668-945B0A3E-1EAE-4CC8-B143-3445A127CE8B Q24202622-BD1A00A4-FE97-4D58-B4AD-0060B8D17AA4

P2860

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

http://www.wikidata.org/entity/Q37788240

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

@en

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

@nl

type

label

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

@en

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

@nl

prefLabel

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

@en

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

@nl

P1433

Q37788240-AA66ABF5-D816-465A-8459-486CBC003A89

P1476

Q37788240-19DB05B6-0542-4A88-B648-926BC036AC16

P2093

Q37788240-0C69E1BE-2E53-4A8D-B5E8-0DF9D129850C

Q37788240-2F4CEF13-187E-4C5D-99D2-A8ABDABA2AA5

Q37788240-C4332313-0971-4D15-88FF-DFACC8FA8DFD

Q37788240-D76FA923-2301-452B-A26A-94166D701AF4

Q37788240-E134C753-8F7C-457A-BE19-66D8A97486EB

Q37788240-EA325DAF-7FD7-4CD4-9254-9EBA216954FC

Q37788240-FDF29D21-329A-48C9-8B26-C780770E78DC

Q37788240-FE4BDAE5-F354-497D-ADF9-D5DC009590F6

P2860

Q37788240-04B94C30-757A-413F-A6A8-13DF4F32E1A2

Q37788240-07561445-56F5-427E-AD1D-9489E4297FB8

Q37788240-0B35C0B2-9B62-48D7-B20A-43319F2DE2B8

Q37788240-2CBB691E-6BF9-4E19-A06F-F97E0426F15E

Q37788240-3CC64E14-F214-4CB5-A6FB-EB59C0C116D6

Q37788240-412A9E42-CDF1-4FEA-B672-D248EF08F31D

Q37788240-54CE31C0-98DC-40FC-9406-D3778D1FC408

Q37788240-56CEF194-844E-40BA-9E20-6383DAF5FD07

Q37788240-58CA9665-92BE-4CF2-A095-E1677686FFE3

Q37788240-5C49A050-2135-42FD-BC0D-5713E1919C18

P304

Q37788240-FB4CB478-8658-400E-9608-978B9DE97915

P31

Q37788240-CBDF64F6-80D8-47F0-B20B-596CD953A5F9

P356

Q37788240-F24478C3-24B2-42BD-BA38-0F75ECC5A1A2

P433

Q37788240-7D420D31-FDB4-4F6F-9F5D-D3CCB8A055FE

P478

Q37788240-14661B16-E43F-4196-AFD0-1C84A9BAB1E8

P577

Q37788240-6644BE20-A472-4A73-8384-4B213AFE47FE

P698

Q37788240-8C9044C6-9B37-417B-A53B-F4E062C8273B

P356

P1433

Expert Review of Anticancer Therapy

P1476

The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Carsten Kobe

http://www.w3.org/2001/XMLSchema#string

Christian Furth

http://www.w3.org/2001/XMLSchema#string

Hans Theodor Eich

http://www.w3.org/2001/XMLSchema#string

Jan Kriz

http://www.w3.org/2001/XMLSchema#string

Markus Dietlein

http://www.w3.org/2001/XMLSchema#string

Michael Fuchs

http://www.w3.org/2001/XMLSchema#string

Peter Borchmann

http://www.w3.org/2001/XMLSchema#string

P2860

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

PET/CT for therapy response assessment in lymphoma.

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?

P304

1419-1428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.10.114

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20836677

http://www.w3.org/2001/XMLSchema#string